Literature DB >> 29924422

Should we be testing for urogenital Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum in men and women? - a position statement from the European STI Guidelines Editorial Board.

P Horner1,2, G Donders3, M Cusini4, M Gomberg5, J S Jensen6, M Unemo7.   

Abstract

At present, we have no evidence that we are doing more good than harm detecting and subsequently treating Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum colonizations/infections. Consequently, routine testing and treatment of asymptomatic or symptomatic men and women for M. hominis, U. urealyticum and U. parvum are not recommended. Asymptomatic carriage of these bacteria is common, and the majority of individuals do not develop any disease. Although U. urealyticum has been associated with urethritis in men, it is probably not causal unless a high load is present (likely carriage in 40-80% of detected cases). The extensive testing, detection and subsequent antimicrobial treatment of these bacteria performed in some settings may result in the selection of antimicrobial resistance, in these bacteria, 'true' STI agents, as well as in the general microbiota, and substantial economic cost for society and individuals, particularly women. The commercialization of many particularly multiplex PCR assays detecting traditional non-viral STIs together with M. hominis, U. parvum and/or U. urealyticum has worsened this situation. Thus, routine screening of asymptomatic men and women or routine testing of symptomatic individuals for M. hominis, U. urealyticum and U. parvum is not recommended. If testing of men with symptomatic urethritis is undertaken, traditional STI urethritis agents such as Neisseria gonorrhoeae, Chlamydia trachomatis, M. genitalium and, in settings where relevant, Trichomonas vaginalis should be excluded prior to U. urealyticum testing and quantitative species-specific molecular diagnostic tests should be used. Only men with high U. urealyticum load should be considered for treatment; however, appropriate evidence for effective treatment regimens is lacking. In symptomatic women, bacterial vaginosis (BV) should always be tested for and treated if detected.
© 2018 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2018        PMID: 29924422     DOI: 10.1111/jdv.15146

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  36 in total

1.  [40-year-old male with urethral discharge : Preparation for the specialist examination: part 13].

Authors:  Susanne Buder
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751

Review 2.  [Current diagnosis and treatment of sexually transmitted infections].

Authors:  Dr C Hein; F M E Wagenlehner
Journal:  Urologe A       Date:  2018-12       Impact factor: 0.639

3.  Molecular prevalence of eight different sexually transmitted infections in a Lebanese major tertiary care center: impact on public health.

Authors:  Nancy El Beayni; Lina Hamad; Christine Nakad; Sose Keleshian; Soha N Yazbek; Rami Mahfouz
Journal:  Int J Mol Epidemiol Genet       Date:  2021-04-15

4.  Detection of sexually transmitted disease-causing pathogens from direct clinical specimens with the multiplex PCR-based STD Direct Flow Chip Kit.

Authors:  Antonio Barrientos-Durán; Adolfo de Salazar; Marta Alvarez-Estévez; Ana Fuentes-López; Beatriz Espadafor; Federico Garcia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-01-04       Impact factor: 3.267

Review 5.  The Role of Ureaplasma spp. in the Development of Nongonococcal Urethritis and Infertility among Men.

Authors:  Michael L Beeton; Matthew S Payne; Lucy Jones
Journal:  Clin Microbiol Rev       Date:  2019-07-03       Impact factor: 26.132

6.  Antimicrobial resistance in clinical isolates of Ureaplasma spp. from samples in Germany.

Authors:  Roger Dumke
Journal:  Antimicrob Agents Chemother       Date:  2021-02-16       Impact factor: 5.191

7.  Molecular Detection of Sexually Transmitted Infections in Women with and without Human Papillomaviruses Infection Who Referred to Tehran West Hospitals in Iran.

Authors:  Seyed Mojtaba Mortazavi; Amin Tarinjoo; Sepideh Dastani; Majid Niyazpour; Samira Dahaghin; Reza Mirnejad
Journal:  Rep Biochem Mol Biol       Date:  2021-10

8.  Evaluation of Clinical, Gram Stain, and Microbiological Cure Outcomes in Men Receiving Azithromycin for Acute Nongonococcal Urethritis: Discordant Cures Are Associated With Mycoplasma genitalium Infection.

Authors:  Evelyn Toh; Xiang Gao; James A Williams; Teresa A Batteiger; Lisa A Coss; Michelle LaPradd; Jie Ren; William M Geisler; Yue Xing; Qunfeng Dong; David E Nelson; Stephen J Jordan
Journal:  Sex Transm Dis       Date:  2022-01-01       Impact factor: 2.830

9.  [Mycoplasma and Ureaplasma spp. in clinical practice of ano-genital infections].

Authors:  M Fernández-Huerta; O Q Pich; M Espasa
Journal:  Rev Esp Quimioter       Date:  2022-04-29       Impact factor: 2.515

10.  Investigation of the association between ten pathogens causing sexually transmitted diseases and high-risk human papilloma virus infection in Shanghai.

Authors:  Li Xie; Qian Li; Xiangrong Dong; Qi Kong; Yuping Duan; Xiong Chen; Xiaoqiang Li; Mao Hong; Tao Liu
Journal:  Mol Clin Oncol       Date:  2021-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.